Acute Otitis Media

0 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Acute Otitis Media has 0 FDA-approved novel treatments. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Acute Otitis Media Clinical Pipeline by Phase

15 industry-sponsored trials across 10 sponsors

Showing 7 of 7 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Lachlan Pharma Holdings	Benzocaine Otic Solution	—	COMPLETED	2017-07-21	NCT03116737
Salvat	DF289	—	COMPLETED	2014-06	NCT01395966
Arbor Pharmaceuticals, Inc.	AR01	—	COMPLETED	2014-03	NCT02044341
Salvat	DF289	—	COMPLETED	2013-05	NCT01404611
Integra LifeSciences Corporation	—	—	COMPLETED	2010-11	NCT01202578
Arbor Pharmaceuticals, Inc.	AR01	—	TERMINATED	2014-06	NCT02074007
Alcon Research	Moxidex otic solution	—	TERMINATED	2011-10	NCT01071902

Showing 7 of 7 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novus Therapeutics, Inc	Amoxicillin-clavulanate	—	COMPLETED	2020-03-09	NCT03818815
Otonomy, Inc.	6 mg ciprofloxacin	—	COMPLETED	2016-06	NCT02719158
Otonomy, Inc.	OTO-201	—	COMPLETED	2015-05	NCT02408796
Currax Pharmaceuticals	Antipyrine and Benzocaine otic solution	—	COMPLETED	2014-09	NCT02037893
Otic Therapy, LLC	Benzocaine	—	COMPLETED	2014-03	NCT02092454
Pfizer	60 mg/kg azithromycin ER	—	COMPLETED	2009-02	NCT00796224
Alcon Research	AL-60371/AL-817 otic suspension	—	TERMINATED	2014-08	NCT01908803

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novus Therapeutics, Inc	—	—	COMPLETED	2019-01-30	NCT03766373

Novel Acute Otitis Media Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (4 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.